Search - tctmd.com

Displaying 381 - 400 of 440

Sort: Relevancy | Date

News Conference News ESC 2017

Fentanyl, Ubiquitous in US Cath Labs, Blunts Antiplatelet Drugs in PCI

Shelley Wood

September 01, 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2017

Caitlin E. Cox

August 31, 2017

News Conference News ESC 2017

ESC Updates Guidelines for Treating STEMI Patients

Michael O'Riordan

August 27, 2017

Studies Supporting Device Modifications Weak, Often Based on Surrogate Endpoints

News Daily News

FDA Clearance of Modified Devices Relies Heavily on Weak Studies, Surrogate Endpoints

Michael O'Riordan

August 16, 2017

News Daily News

Many Stroke Patients Stop Statins or Never Start, With Dire Consequences

Michael O'Riordan

August 02, 2017

News Featured Fellow

Nirmanmoh Bhatia, MD

Yael L. Maxwell

July 11, 2017

News Featured Fellow

Ankur Kalra, MD

Yael L. Maxwell

May 26, 2017

News Daily News

Opened Data: Analysis of Requests for NHLBI Trial Data May Allay Some Concerns

Shelley Wood

March 29, 2017

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Shelley Wood

March 10, 2017

News Conference News CRT 2017

Same-Day Discharge After Transradial PCI Safe, Feasible, With Significant Cost Savings

Michael O'Riordan

February 23, 2017

News Daily News

Apples and Pears: Genetic Analysis Points to Causal Role for Belly Fat in Heart Disease and Diabetes

Yael L. Maxwell

February 14, 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2017

Caitlin E. Cox

February 01, 2017

News Features

Be It Resolved: E-Cigarettes May Help Smokers Cut Back, but Quit Altogether? The Jury’s Out

Caitlin E. Cox

January 20, 2017

News Daily News

Registry Hints Staged Intervention Reduces Mortality in STEMI Patients With Multivessel CAD, but Controversy Remains

L.A. McKeown

January 09, 2017

News Daily News

‘Appropriate’ Use of Revascularization in ACS: Updated Criteria Released at Last

Caitlin E. Cox

December 21, 2016

News Daily News

The Smartphone Will See You Now: Clinical Research Can Be Done via App

Yael L. Maxwell

December 16, 2016

News Opinion Fellow Talk

Top 10 Tricks on Medical Liability

Yael L. Maxwell

November 23, 2016

News Daily News

FDA-Funded or Not: Final Rule Makeover Means All Research Must Be Registered and Report Results

Yael L. Maxwell

September 23, 2016

News Daily News

TAVR as an Option for Intermediate-Risk Patients: Physicians Respond

Yael L. Maxwell

August 24, 2016

News Daily News

FDA Declines to Approve Portola’s Reversal Agent for Factor Xa Inhibitors

Michael O'Riordan

August 18, 2016

Advertisement

Fentanyl, Ubiquitous in US Cath Labs, Blunts Antiplatelet Drugs in PCI

TCTMD’s Top 10 Most Popular Stories for August 2017

ESC Updates Guidelines for Treating STEMI Patients

FDA Clearance of Modified Devices Relies Heavily on Weak Studies, Surrogate Endpoints

Many Stroke Patients Stop Statins or Never Start, With Dire Consequences

Nirmanmoh Bhatia, MD

Ankur Kalra, MD

Opened Data: Analysis of Requests for NHLBI Trial Data May Allay Some Concerns

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Same-Day Discharge After Transradial PCI Safe, Feasible, With Significant Cost Savings

Apples and Pears: Genetic Analysis Points to Causal Role for Belly Fat in Heart Disease and Diabetes

TCTMD’s Top 10 Most Popular Stories for January 2017

Be It Resolved: E-Cigarettes May Help Smokers Cut Back, but Quit Altogether? The Jury’s Out

Registry Hints Staged Intervention Reduces Mortality in STEMI Patients With Multivessel CAD, but Controversy Remains

‘Appropriate’ Use of Revascularization in ACS: Updated Criteria Released at Last

The Smartphone Will See You Now: Clinical Research Can Be Done via App

Top 10 Tricks on Medical Liability

FDA-Funded or Not: Final Rule Makeover Means All Research Must Be Registered and Report Results

TAVR as an Option for Intermediate-Risk Patients: Physicians Respond

FDA Declines to Approve Portola’s Reversal Agent for Factor Xa Inhibitors

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content